Cirrhosis natural history, complications and prognosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 8: Line 8:
===Natural History===
===Natural History===
*The symptoms of cirrhosis usually develop in the fourth or fifth decade of life, and start with symptoms such as [[fever]], [[anorexia]], [[fatigue]], [[weakness]], [[nausea]], [[vomiting]], [[weight loss]] and [[jaundice]].<ref name="pmid25203153">{{cite journal |vauthors=Sajja KC, Mohan DP, Rockey DC |title=Age and ethnicity in cirrhosis |journal=J. Investig. Med. |volume=62 |issue=7 |pages=920–6 |year=2014 |pmid=25203153 |pmc=4172494 |doi=10.1097/JIM.0000000000000106 |url=}}</ref><ref name="pmid9683971">{{cite journal |vauthors=Williams EJ, Iredale JP |title=Liver cirrhosis |journal=Postgrad Med J |volume=74 |issue=870 |pages=193–202 |year=1998 |pmid=9683971 |pmc=2360862 |doi= |url=}}</ref><ref name="pmid18328931">{{cite journal |vauthors=Schuppan D, Afdhal NH |title=Liver cirrhosis |journal=Lancet |volume=371 |issue=9615 |pages=838–51 |year=2008 |pmid=18328931 |pmc=2271178 |doi=10.1016/S0140-6736(08)60383-9 |url=}}</ref>  
*The symptoms of cirrhosis usually develop in the fourth or fifth decade of life, and start with symptoms such as [[fever]], [[anorexia]], [[fatigue]], [[weakness]], [[nausea]], [[vomiting]], [[weight loss]] and [[jaundice]].<ref name="pmid25203153">{{cite journal |vauthors=Sajja KC, Mohan DP, Rockey DC |title=Age and ethnicity in cirrhosis |journal=J. Investig. Med. |volume=62 |issue=7 |pages=920–6 |year=2014 |pmid=25203153 |pmc=4172494 |doi=10.1097/JIM.0000000000000106 |url=}}</ref><ref name="pmid9683971">{{cite journal |vauthors=Williams EJ, Iredale JP |title=Liver cirrhosis |journal=Postgrad Med J |volume=74 |issue=870 |pages=193–202 |year=1998 |pmid=9683971 |pmc=2360862 |doi= |url=}}</ref><ref name="pmid18328931">{{cite journal |vauthors=Schuppan D, Afdhal NH |title=Liver cirrhosis |journal=Lancet |volume=371 |issue=9615 |pages=838–51 |year=2008 |pmid=18328931 |pmc=2271178 |doi=10.1016/S0140-6736(08)60383-9 |url=}}</ref>  
*If left untreated, patients with cirrhosis may progress to develop [[ascites]], [[esophageal varices]], [[hepatic encephalopathy]], [[spontaneous bacterial peritonitis]], [[Hepatopulmonary syndrome|hepatopulmonary]] and [[hepatorenal syndrome]].<ref name="pmid29128051">{{cite journal |vauthors=Lindenmeyer CC, McCullough AJ |title=The Natural History of Nonalcoholic Fatty Liver Disease-An Evolving View |journal=Clin Liver Dis |volume=22 |issue=1 |pages=11–21 |year=2018 |pmid=29128051 |doi=10.1016/j.cld.2017.08.003 |url=}}</ref><ref name="pmid25230084">{{cite journal |vauthors=Bloom S, Kemp W, Lubel J |title=Portal hypertension: pathophysiology, diagnosis and management |journal=Intern Med J |volume=45 |issue=1 |pages=16–26 |year=2015 |pmid=25230084 |doi=10.1111/imj.12590 |url=}}</ref>  
*If left untreated, patients with cirrhosis may progress to develop [[ascites]], [[esophageal varices]], [[hepatic encephalopathy]], [[spontaneous bacterial peritonitis]], [[Hepatopulmonary syndrome|hepatopulmonary]] and [[hepatorenal syndrome]].<ref name="pmid29128051">{{cite journal |vauthors=Lindenmeyer CC, McCullough AJ |title=The Natural History of Nonalcoholic Fatty Liver Disease-An Evolving View |journal=Clin Liver Dis |volume=22 |issue=1 |pages=11–21 |year=2018 |pmid=29128051 |doi=10.1016/j.cld.2017.08.003 |url=}}</ref><ref name="pmid25230084">{{cite journal |vauthors=Bloom S, Kemp W, Lubel J |title=Portal hypertension: pathophysiology, diagnosis and management |journal=Intern Med J |volume=45 |issue=1 |pages=16–26 |year=2015 |pmid=25230084 |doi=10.1111/imj.12590 |url=}}</ref><ref name="pmid9683971">{{cite journal |vauthors=Williams EJ, Iredale JP |title=Liver cirrhosis |journal=Postgrad Med J |volume=74 |issue=870 |pages=193–202 |year=1998 |pmid=9683971 |pmc=2360862 |doi= |url=}}</ref><ref name="pmid8550036">{{cite journal |vauthors=Arroyo V, Ginès P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, Reynolds TB, Ring-Larsen H, Schölmerich J |title=Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club |journal=Hepatology |volume=23 |issue=1 |pages=164–76 |year=1996 |pmid=8550036 |doi=10.1002/hep.510230122 |url=}}</ref><ref name="pmid1833293">{{cite journal |vauthors=Wilkinson SP, Moore KP, Arroyo V |title=Pathogenesis of ascites and hepatorenal syndrome |journal=Gut |volume=Suppl |issue= |pages=S12–7 |year=1991 |pmid=1833293 |pmc=1405222 |doi= |url=}}</ref><ref name="pmid1435935">{{cite journal |vauthors=Epstein M |title=The hepatorenal syndrome--newer perspectives |journal=N. Engl. J. Med. |volume=327 |issue=25 |pages=1810–1 |year=1992 |pmid=1435935 |doi=10.1056/NEJM199212173272509 |url=}}</ref>  
*The general course of cirrhosis is characterized by a long stage of compensation, which may be followed by deterioration and development of specific complications.
*The general course of cirrhosis is characterized by a long stage of compensation, which may be followed by deterioration and development of specific complications.
*Life threatening complications may develop in almost any patient. Once the first complication in a patient with cirrhosis is seen, it is soon followed by numerous other complications that significantly decrease [[life expectancy]].   
*Life threatening complications may develop in almost any patient. Once the first complication in a patient with cirrhosis is seen, it is soon followed by numerous other complications that significantly decrease [[life expectancy]].   

Revision as of 21:03, 15 December 2017

Cirrhosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cirrhosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Tertiary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case studies

Case #1

Cirrhosis natural history, complications and prognosis On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cirrhosis natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cirrhosis natural history, complications and prognosis

CDC on Cirrhosis natural history, complications and prognosis

Cirrhosis natural history, complications and prognosis in the news

Blogs on Cirrhosis natural history, complications and prognosis

Directions to Hospitals Treating Cirrhosis

Risk calculators and risk factors for Cirrhosis natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Sudarshana Datta, MD [2]

Overview

Cirrhosis is an irreversible process, the course of which is highly variable in patients. The natural history progresses in such a way that there is a lengthy stage of compensation, followed by the development of complications and sequelae as a result of the cirrhosis. The devastating complications include complete liver failure or the development of hepatocellular carcinoma. Other complications include portal hypertension, ascites, jaundice, itching, esophageal varices, spontaneous bacterial peritonitis, hepatic encephalopathy, hepatorenal syndrome, hepatopulmonary syndrome and cardiomyopathy. Prognosis depends on the causes, existing complications and a variety of factors which make the prediction of life expectancy questionable. There are scores which classify disease severity and to determine suitability for liver transplantation in patients.

Natural History

Decompensated Cirrhosis

Complications

Prognosis

  • The prognosis of patients varies with existing function of the liver, etiology of cirrhosis, progression of the disease, development of HCC and ability to withstand therapy.
Well-Compensated, no alcohol 35% mortality at 2 years
Onset of Ascites 50% mortality at 2 years
Variceal bleeding 65% mortality at 1 year (35% short-term mortality)

Poor Prognostic Factors

Scoring Systems

References

  1. Sajja KC, Mohan DP, Rockey DC (2014). "Age and ethnicity in cirrhosis". J. Investig. Med. 62 (7): 920–6. doi:10.1097/JIM.0000000000000106. PMC 4172494. PMID 25203153.
  2. 2.0 2.1 Williams EJ, Iredale JP (1998). "Liver cirrhosis". Postgrad Med J. 74 (870): 193–202. PMC 2360862. PMID 9683971.
  3. Schuppan D, Afdhal NH (2008). "Liver cirrhosis". Lancet. 371 (9615): 838–51. doi:10.1016/S0140-6736(08)60383-9. PMC 2271178. PMID 18328931.
  4. 4.0 4.1 Lindenmeyer CC, McCullough AJ (2018). "The Natural History of Nonalcoholic Fatty Liver Disease-An Evolving View". Clin Liver Dis. 22 (1): 11–21. doi:10.1016/j.cld.2017.08.003. PMID 29128051.
  5. Bloom S, Kemp W, Lubel J (2015). "Portal hypertension: pathophysiology, diagnosis and management". Intern Med J. 45 (1): 16–26. doi:10.1111/imj.12590. PMID 25230084.
  6. Arroyo V, Ginès P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, Reynolds TB, Ring-Larsen H, Schölmerich J (1996). "Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club". Hepatology. 23 (1): 164–76. doi:10.1002/hep.510230122. PMID 8550036.
  7. Wilkinson SP, Moore KP, Arroyo V (1991). "Pathogenesis of ascites and hepatorenal syndrome". Gut. Suppl: S12–7. PMC 1405222. PMID 1833293.
  8. Epstein M (1992). "The hepatorenal syndrome--newer perspectives". N. Engl. J. Med. 327 (25): 1810–1. doi:10.1056/NEJM199212173272509. PMID 1435935.
  9. García-Criado A, Castellón D (2017). "Presentation of the series "Cirrhosis of the liver and its complications"". Radiologia. doi:10.1016/j.rx.2017.10.003. PMID 29169606.
  10. 10.0 10.1 Rodriguez-Roisin R, Krowka MJ, Herve P, Fallon MB; ERS Task Force Pulmonary-Hepatic Vascular Disorders (PHD) Scientific Committee. Pulmonary-Hepatic vascular Disorders (PHD). Eur Respir J 2004;24:861-80. PMID 15516683.
  11. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the esophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-9. PMID 4541913.

Template:WH Template:WS